Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-cell Therapy, in US Adults with B-ALL

Key Points

• Cytokine release syndrome and neurotoxicity lead to significant healthcare costs, impacting patient management.
• The analysis identified average treatment costs exceeding $100,000 for incidents of CRS and ICANS post CAR T-cell therapy.
• Observational analysis assessed healthcare expenditures in relation to treatment outcomes and adverse events.
• Impacts and financial burdens from these syndromes highlight the need for improved cost management strategies.